Galvanize Therapeutics, Inc
$2.7M 830 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
CVRx, Inc.
CVRx, Inc. reported $2,678,443.68 across General Payments, Research, and Ownership to 16,025 physicians and teaching hospitals across 16,375 transactions.
- $2.7M Top quartile payer
- All-tracks total
- 16,375 Top 10% volume
- Transactions
- 16,025 Top 10% reach
- Recipients
- +$282.9K
- General Payments vs PY2023
CVRx, Inc. reported $2,678,443.68 across all CMS Open Payments tracks (General + Research + Ownership) to 16,025 physicians and teaching hospitals in Program Year 2024 - ranking #389 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,517,990.54, averaging $167.14 per recipient.
How CVRx, Inc.'s $2.7M all-tracks total breaks down
CVRx, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
C
68/100
Total payments
F
35/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer cvrx-inc CVRx, Inc.
$2.7M · #389/1,925 · 0.0% industry · PY2024
- TOT $2.7M
- RANK #389
- SHARE 0.0%
- TXN 16,375
- RCP 16,025
- CAT 3
- GEN $1.5M
- ΔGEN +$282.9K
- TOP1 3.9%
- PY 2024
Volume peers
Nearest volume peer: Galvanize Therapeutics, Inc ($2.7M)
CVRx, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
CVRx, Inc.'s CMS-reported General Payments increased by $282.9K (+22.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: CVRX, INC.PY2023: CVRX, INC.PY2024: CVRx, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,235,117.26
- PY2024
- $1,517,990.54
What the Data Shows for CVRx, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For CVRx, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
"Food and Beverage" leads the 3-category general-payment breakdown below at $670.8K (44.2% of General Payments, 15,201 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Food and Beverage" leads CVRx, Inc.'s 3-category general-payment breakdown at $670.8K, 44.2% of the reported total.
How CVRx, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $670.8K | 15,201 | 44.2% |
| Consulting Fee | $655.2K | 234 | 43.2% |
| Travel and Lodging | $192.0K | 590 | 12.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $241,008.05 (15.9%) of $1,517,990.54 in this company's General Payments records across 7,074 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for CVRx, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Gurusher Singh Panjrath
$58,952.87 across 68 reported transactions
- 2
Dmitry M Yaranov
$55,709.02 across 76 reported transactions
- 3
Joseph Esaum Rahman
$46,494.41 across 46 reported transactions
- 4
Albert J Hicks III
$41,096.29 across 48 reported transactions
- 5
Amarinder Singh Bindra
$38,755.46 across 55 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
CVRx, Inc. ranks #389 of 1,925 by total payments (top 20% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,695 of 1,838 by HHI (bottom 8% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Biotronik Inc. : $2.4M total payments, HHI 102
- CSL Plasma Inc. : $17.9M total payments, HHI 100
- Ardelyx, Inc. : $1.8M total payments, HHI 99
- Synthes GmbH : $2.5M total payments, HHI 99
- ANI Pharmaceuticals, Inc. : $1.1M total payments, HHI 98
- Arcutis Biotherapeutics, Inc. : $5.0M total payments, HHI 97
- CVRx, Inc. (this company) : $1.5M total payments, HHI 97
- Peerless Surgical Inc. : $139.0K total payments, HHI 96
- Gemini Mountain Medical, LLC : $85.4K total payments, HHI 96
- InSightec,Inc : $120.8K total payments, HHI 96
- Mid-Atlantic Surgical Systems, LLC : $92.4K total payments, HHI 95
- Tempus AI, Inc : $683.5K total payments, HHI 95
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as CVRx, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about CVRx, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with CVRx, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Calyxo, Inc.
$2.7M 1,299 recipients
Compare payment profiles
Vertical Orthopaedics, Inc.
$2.7M 19 recipients
Compare payment profiles
Nanovis LLC
$2.7M 24 recipients
Compare payment profiles
Global Blood Therapeutics, Inc.
$2.7M 0 recipients
Compare payment profiles
Tulsa Dental Products LLC
$2.7M 122 recipients
Compare payment profiles
Put this to use
CVRx, Inc. ranks #389 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See where CVRx, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just CVRx, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.